CN100336555C - Danshen capsule for antitumour and its preparation technology - Google Patents
Danshen capsule for antitumour and its preparation technology Download PDFInfo
- Publication number
- CN100336555C CN100336555C CNB031561004A CN03156100A CN100336555C CN 100336555 C CN100336555 C CN 100336555C CN B031561004 A CNB031561004 A CN B031561004A CN 03156100 A CN03156100 A CN 03156100A CN 100336555 C CN100336555 C CN 100336555C
- Authority
- CN
- China
- Prior art keywords
- grams
- weight portions
- radix
- parched
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 title claims 2
- 238000005516 engineering process Methods 0.000 title abstract description 6
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 title description 4
- 244000132619 red sage Species 0.000 title description 4
- 241000208340 Araliaceae Species 0.000 claims abstract description 26
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 26
- 235000008434 ginseng Nutrition 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 241000287828 Gallus gallus Species 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000009636 Huang Qi Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 235000006793 Artemisia stelleriana Nutrition 0.000 claims description 9
- 244000252230 Artemisia stelleriana Species 0.000 claims description 9
- 240000005308 Juniperus chinensis Species 0.000 claims description 9
- 241000131808 Scolopendra Species 0.000 claims description 9
- 241000522620 Scorpio Species 0.000 claims description 9
- 235000006413 coastal sagewort Nutrition 0.000 claims description 9
- 210000003038 endothelium Anatomy 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000009490 scorpio Substances 0.000 claims description 9
- 239000000341 volatile oil Substances 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 3
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 3
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 235000013330 chicken meat Nutrition 0.000 claims 3
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims 2
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 238000000227 grinding Methods 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 17
- 230000001737 promoting effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 8
- 210000000952 spleen Anatomy 0.000 abstract description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 5
- 208000026435 phlegm Diseases 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 238000002512 chemotherapy Methods 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 210000000822 natural killer cell Anatomy 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 235000017276 Salvia Nutrition 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008479 Chest Pain Diseases 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 241001673966 Magnolia officinalis Species 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 240000006023 Trichosanthes kirilowii Species 0.000 abstract 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000009993 protective function Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000012850 discrimination method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000037842 advanced-stage tumor Diseases 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000202052 Poncirus trifoliata Species 0.000 description 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to innovative Chinese patent medicine for resisting tumors, particularly to a salvia capsule recipe, recipe components and a preparation technology thereof. The present invention is characterized in that traditional Chinese medicinal materials such as ginseng (raw radix ginseng), milk vetch (raw), atractylodes (fried by bran), chicken's gizzard-membrane (raw), trichosanthes kirilowii, pinellia tuber (clean), magnolia bark, bitter orange (fried), curcuma root, salvia, scorpions and centipedes as raw materials; an advanced technical technology is adopted for respectively extracting effective components for preparing a Chinese medicine preparation with convenient carrying and administration, and high therapeutic effect. The present invention has the functions of replenishing qi, invigorating spleens, regulating the qi, eliminating phlegm, promoting blood circulation and dispelling stasis, and is used for treating lung cancer, gastrointestinal cancer, breast cancer, etc. The present invention improves the symptoms of tumor (spleen deficiency and phlegm stasis symptoms) patients of chest pain, painful distension over hypochondrium, white complexions, poor appetite, little breath, no speak, short breath, etc. The present invention obviously enhances a chemotherapeutic effect when the present invention is combined with chemotherapy for treatment, enhances the life quality of chemotherapeutic patients, enhances the activity of NK cells, and has a protective function for reducing white cells in the chemotherapy.
Description
The present invention relates to a kind of antineoplastic Chinese patent medicine, particularly Danshen capsule and preparation technology thereof.It is characterized in that with Radix Ginseng, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Endothelium Corneum Gigeriae Galli, Chinese juniper beach wormwood, the Rhizoma Pinelliae, Cortex Magnoliae Officinalis, Fructus Aurantii, Radix Curcumae, Radix Salviae Miltiorrhizae, Scorpio, Scolopendra, be raw material, extract a kind of innovation Chinese medicine preparation that active ingredient forms through scientific technology.
Tumor has now become the healthy and disease more widely of serious threat human life, and there are New Development malignant tumor 9,000,000 people in the whole world every year, and 7,000,000 people that reach that die from this disease.In state-owned 1,200,000,000 populations, annual nearly 1,600,000 New Development malignant tumor patients, annual nearly 1,300,000 people die from cancer, so cancer is positive excess, and to cross that cardiovascular and cerebrovascular disease forms be first cause of death.The control of tumor has become the problem of extensively paying attention in the world wide, countries in the world have been dropped into a large amount of human and material resources and studied every year, but up to now, still not fully aware of to its cause of disease, pathology, Therapeutic Method does not still have important breakthrough, many countries have noticed and have used the method for traditional medicine to prevent and treat, and particularly pay special attention to having thousands of years historical Chinese medicines.Chinese medicine is the treasure-house of a greatness, and it is the wisdom crystallization that China people combat the disease for a long time, be applied to the method excavation of modern science and develop it, and be once to have a extensive future and arduous cause in the field of treatment malignant tumor.
The Chinese medicine tumor has profuse argumentation in the successive dynasties Chinese medical theory, method is various, the means uniqueness.The existing determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs Therapeutic Method of pressing Chinese medical theory system rule has peculiar methods such as folk prescription that people are summed up, folk prescription, proved recipe again in practical exploration." ginseng is red " capsular development is according to the Chinese medical theory strengthening vital QI to eliminate pathogenic factors rule of treatment, and holds the crystallization of the practical experience of proved recipe.The purpose of this invention both had been the utilization Chinese medical theory, was used for various symptoms after the auxiliary treatment middle and advanced stage tumor stomach patient chemotherapy in conjunction with a large amount of practical explorations of clinical application, improved its quality of life, delayed life.Said preparation effective percentage height, no toxicity, for auxiliary treatment middle and advanced stage tumor stomach patient increases new effective therapy again, it provides new illustration again for Chinese medicine auxiliary treatment tumor stomach
Purpose of the present invention: be to adopt brand-new prescription and preparation process, selected the Radix Ginseng strongly invigorating primordial QI for use, invigorating the spleen to benefit the lung, promoting the production of body fluid to quench thirst, the Fructus Alpiniae Oxyphyllae of calming the nerves.Radix Astragali benefiting qi and raising yang, strengthening superficial resistance to stop perspiration, inducing diuresis to remove edema, promoting pus discharge and tissue regeneration strengthening, the two is monarch drug altogether.The Rhizoma Atractylodis Macrocephalae
(parched with bran), Endothelium Corneum Gigeriae Galli, Chinese juniper beach wormwood, the Rhizoma Pinelliae
(clearly)Be ministerial drug altogether.Rhizoma Atractylodis Macrocephalae sweetness and bitterness in the side and temperature is the key medicine of invigorating the spleen and benefiting QI is share with monarch drug Radix Ginseng, the Radix Astragali, strengthens two flavor replenishing QI to invigorate the spleen effects, to set upright Pei Qiben.The Endothelium Corneum Gigeriae Galli nature and flavor are sweet flat, have strengthening the spleen to promote digestion, the eliminating mass fossilization.The Chinese juniper beach wormwood is sweet cold, is the product of removing heat-phlegm, the chest stuffiness relieving knot.The Rhizoma Pinelliae
(clearly)The hot bitter dry temperature of loosing is logical, and merit is arrogated to oneself drying dampness to eliminate phlegm, dissolving lump and resolving mass.Cortex Magnoliae Officinalis, Fructus Aurantii, Radix Curcumae, Radix Salviae Miltiorrhizae are adjuvant drug altogether.Cortex Magnoliae Officinalis toil warm-dryness syndrome, function circulation of qi promoting removing food stagnancy, dampness is removed full, for stagnation of QI due to dyspepsia, wet resistance distension good effect is arranged all.The Fructus Aurantii picric acid is slightly cold, and has the chest stuffiness relieving of regulating the flow of vital energy, and the merit of circulation of qi promoting removing food stagnancy is for controlling stagnation of QI key medicine uncomfortable in chest.Trifoliate orange, plain two medicines share, and the circulation of qi promoting removing food stagnancy is imitated good.Radix Curcumae, Radix Salviae Miltiorrhizae are all cold promoting blood circulation to disperse blood clots and relieves pain medicine, are treatment abdominal mass caking product commonly used, and wherein Radix Curcumae again can the circulation of qi promoting dispersing the stagnated live-QI to relieve the stagnation of QI, and the capable then blood of gas is capable, with the power of strengthening invigorating blood circulation.The Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, Shan Zhi lumps in the chest and abdomen.More than four medicines share play altogether eliminate indigestion and phlegm, the merit of promoting flow of QI and blood, at pathological products such as expectorant knot, wet poly-, the stagnation of QI, blood stasis, short its dissipation is dissolved, and focuses on eliminating evil.The thing of Scorpio, Scolopendra wriggling, property is apt to away scurry, and goes into network and picks poison, can draw the through sick institute of all medicines, has the tying-in effect, so messenger drug in the side of being.Ginseng is red " capsule is made up of 12 flavor Chinese medicines, and the principle according to the formulation quality standard has designed qualitative and quantitative analysis method.
Differentiate item: (1) is owing to the former powder of medical material of Scolopendra and Scorpio is used as medicine, so formulate both microscopical identification methods.
(2) with the ginsenoside Rg
1, Re, Rb
1With astragaloside be the discrimination method that reference substance has been formulated the Radix Ginseng and the Radix Astragali.
(3) with Tanshinone I I
AFormulated the discrimination method of Radix Salviae Miltiorrhizae for reference substance.
(4) with the Hesperidin be the discrimination method that reference substance has been formulated Fructus Aurantii.
Assay item:, therefore, adopt the HPLC method to formulate the content assaying method of ginsenoside Re, Rgl in the Radix Ginseng because Radix Ginseng is that monarch drug belongs to valuable medicinal again.And stipulate that every contains the ginsenoside and must not be less than 0.08mg.
The present invention is achieved in that and selects Radix Ginseng for use
(Radix Ginseng)100g, Radix Salviae Miltiorrhizae 75g add 80% ethanol heating extraction three times, and each one hour, filter, medicinal residues are standby, and merging filtrate reclaims ethanol and is concentrated into relative density 1.18～1.20 (50 ℃).Get the Rhizoma Atractylodis Macrocephalae
(parched with bran)60g, Cortex Magnoliae Officinalis 60g, Radix Curcumae 100g, Fructus Aurantii
(stir-fry)60g, it is an amount of to add water, extracts volatile oil, medicinal residues and the Radix Astragali
(life)150g, Chinese juniper beach wormwood 90g, the Rhizoma Pinelliae
(clearly)60g and Radix Ginseng
(Radix Ginseng), Radix Salviae Miltiorrhizae decoction dregs merges, decoct with water three times, each one hour, filter, merging filtrate, being concentrated into relative density is 1.18～1.20 (50 ℃).Merge with above-mentioned ethanol extraction concentrated solution, continuing to be concentrated into relative density is 1.30～1.35 (50 ℃).Add Endothelium Corneum Gigeriae Galli
(life)100g Scorpio 30g Scolopendra 45g fine powder mixing, dry below 80 ℃, pulverize, standby.Volatile oil and beta-schardinger dextrin-be in 1: 10 ratio inclusion, and cold preservation is filtered, and be dry below 40 ℃, and crushing screening mixes with above-mentioned dried cream powder and to add the appropriate amount of starch mixing, adorns 1000 capsules, promptly.
4. advantage of the present invention: because dosage form of the present invention is capsule, carry, taking convenience, boiled water is taken after mixing it with water, and 1 is oral, and every day 3 times, each 6, medication 42 days was a course of treatment.Owing to add Endothelium Corneum Gigeriae Galli
(life)100g Scorpio 30g Scolopendra 45g fine powder has reduced the adjuvant use amount; Radix Ginseng
(Radix Ginseng), Radix Salviae Miltiorrhizae adds 80% ethanol heating extraction three times, each one hour, filter, medicinal residues are standby, merging filtrate reclaims ethanol to relative density 1.18～1.20 (50 ℃).Get the Rhizoma Atractylodis Macrocephalae
(parched with bran), Cortex Magnoliae Officinalis, Radix Curcumae, Fructus Aurantii
(stir-fry), it is an amount of to add water, extracts volatile oil, medicinal residues and the Radix Astragali
(life), Chinese juniper beach wormwood, the Rhizoma Pinelliae
(clearly)G and Radix Ginseng
(Radix Ginseng), Radix Salviae Miltiorrhizae decoction dregs merges, decoct with water three times, each one hour, abundant its effective ingredient of extraction and application, by pharmacodynamic experiment, the result shows: when using with 4～16g/kg dosage filling stomach, be 37.79～50.57% to the tumour inhibiting rate of S180 murine sarcoma; Tumour inhibiting rate 32.91～49.28%. to EAC mouse ascites cancer; Tumour inhibiting rate to HepA hepatocarcinoma is 21.71～43.43%; This product is composed each dosage treated animal body weight to three kinds of tumors does not have obvious reduction effect; The heavy dose of group of " ginseng is red " capsule can obviously strengthen tumor-bearing mice splenocyte transformation function and improve the clean up speed of tumor-bearing mice to carbon granules; Have raising tumor-bearing mice spleen NK cytoactive, promote the NK cells in vitro to kill and wound the effect of K562 cytoactive; Cyclophosphamide is caused the reduction of mice peripheral blood leucocyte certain protective role is arranged; This medicine also has the effect that promotes tumor-bearing mice T lymphocyte immunity and improve the mononuclear cell phagocytic function.Long toxicity test is with 62.5,31.3 times and blank group suitable and clinical people's consumption (0.16g/kg).Irritate the stomach secondary every day, successive administration 90 days, the result shows, rats eating, activity, fur is good, comparing before each treated animal body weight and the administration all has increase, and the hematology detects, blood biochemical is learned every index and organ coefficient and the relatively more equal no significant differences (P＞0.05) of matched group such as detections.Internal organs such as each treated animal heart of pathological examination, liver, spleen, lung, kidney, brain, stomach, small intestinal, uterus, testis and matched group relatively there is no obvious pathomorphology and change.
Accompanying drawing: be the technological process that proposes according to the present invention.
Embodiment: select Radix Ginseng for use
(Radix Ginseng)100g, Radix Salviae Miltiorrhizae 75g add 80% ethanol heating extraction three times, and each one hour, filter, medicinal residues are standby, and merging filtrate reclaims ethanol and is concentrated into relative density 1.18～1.20 (50 ℃).Get the Rhizoma Atractylodis Macrocephalae
(parched with bran)60g, Cortex Magnoliae Officinalis 60g, Radix Curcumae 100g, Fructus Aurantii
(stir-fry)60g, it is an amount of to add water, extracts volatile oil, medicinal residues and the Radix Astragali
(life)150g, Chinese juniper beach wormwood 90g, the Rhizoma Pinelliae
(clearly)60g and Radix Ginseng
(Radix Ginseng), Radix Salviae Miltiorrhizae decoction dregs merges, decoct with water three times, each one hour, filter, merging filtrate, being concentrated into relative density is 1.18～1.20 (50 ℃).Merge with above-mentioned ethanol extraction concentrated solution, continuing to be concentrated into relative density is 1.30～1.35 (50 ℃).Add Endothelium Corneum Gigeriae Galli
(life)100g Scorpio 30g Scolopendra 45g fine powder mixing, dry below 80 ℃, pulverize, standby.Volatile oil and beta-schardinger dextrin-be in 1: 10 ratio inclusion, and cold preservation is filtered, and be dry below 40 ℃, and crushing screening mixes with above-mentioned dried cream powder and to add the appropriate amount of starch mixing, adorns 1000 capsules, promptly gets Danshen capsule.
Claims (3)
1. anti-tumor drug, this medicine is a capsule preparations, it is characterized in that: contain at least 0.08 milligram ginsenoside Re and Rg1 in every capsules, and the crude drug prescription that per 1000 capsules adopt is: Radix Ginseng's 100 grams, Radix Astragali 150 grams, Rhizoma Atractylodis Macrocephalae (parched with bran) 60 grams, live chickens Endothelium corneum 100 grams, Chinese juniper beach wormwood 90 grams, Rhizoma Pinelliae 60 grams, Cortex Magnoliae Officinalis 60 grams, Fructus Aurantii (parched) 60 grams, Radix Curcumae 100 grams, Radix Salviae Miltiorrhizae 75 grams, Scorpio 30 grams, Scolopendra 45 grams.
2. a preparing anti-tumor medicine method is characterized in that comprising the steps:
(1) according to following prescription weighting raw materials: Radix Ginseng's 10 weight portions, Radix Astragali 15 weight portions, Rhizoma Atractylodis Macrocephalae (parched with bran) 6 weight portions, live chickens Endothelium corneum 10 weight portions, Chinese juniper beach wormwood 9 weight portions, Rhizoma Pinelliae 6 weight portions, Cortex Magnoliae Officinalis 6 weight portions, Fructus Aurantii (parched) 6 weight portions, Radix Curcumae 10 weight portions, Radix Salviae Miltiorrhizae 7.5 weight portions, Scorpio 3 weight portions, Scolopendra 4.5 weight portions;
(2) get Radix Ginseng, Radix Salviae Miltiorrhizae and add 80% ethanol extraction 3 times, each 1 hour, filter and collect filtrate, reclaiming ethanol and filtrate is concentrated into relative density at 50 degrees centigrade is 1.18-1.20, medicinal residues are standby;
(3) get Rhizoma Atractylodis Macrocephalae (parched with bran), Cortex Magnoliae Officinalis, Radix Curcumae, Fructus Aurantii (parched), it is an amount of to add water, extracts volatile oil, and medicinal residues are standby;
(4) Radix Astragali, Chinese juniper beach wormwood, Rhizoma Pinelliae and step (2) gained medicinal residues and step (3) gained medicinal residues are merged, decoct with water 3 times, each 1 hour, filtering collection filtrate and being concentrated into relative density was 1.18-1.20;
(5) concentrated filtrate of concentrated filtrate that step (2) is obtained and step (4) acquisition merges, and continuing to be concentrated into relative density in 50 degrees centigrade is 1.30-1.35;
(6) fine powder that live chickens Endothelium corneum, Scorpio, Scolopendra are ground into mixes with the concentrated solution that step (5) obtains, and is dry below 80 degrees centigrade, standby after pulverizing;
(7) volatile oil that step (3) is made and cycloheptaamylose be according to 1: 10 ratio inclusion, after the filtration, and dry below 40 degrees centigrade, grinding and sieving;
(8) dry powder blend of powder that step (7) is obtained and step (6) acquisition.
3. method according to claim 2 comprises also that wherein the mixture with step (8) gained is prepared into capsular step, and every of wherein said capsule contains at least 0.08 milligram ginsenoside Re and Rg1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031561004A CN100336555C (en) | 2003-09-01 | 2003-09-01 | Danshen capsule for antitumour and its preparation technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031561004A CN100336555C (en) | 2003-09-01 | 2003-09-01 | Danshen capsule for antitumour and its preparation technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1589861A CN1589861A (en) | 2005-03-09 |
| CN100336555C true CN100336555C (en) | 2007-09-12 |
Family
ID=34598310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031561004A Expired - Lifetime CN100336555C (en) | 2003-09-01 | 2003-09-01 | Danshen capsule for antitumour and its preparation technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100336555C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1355031A (en) * | 2000-11-24 | 2002-06-26 | 赵清涛 | Medicine for treating tumor and its preparing process |
-
2003
- 2003-09-01 CN CNB031561004A patent/CN100336555C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1355031A (en) * | 2000-11-24 | 2002-06-26 | 赵清涛 | Medicine for treating tumor and its preparing process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1589861A (en) | 2005-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102078520B (en) | Chinese medicinal preparation for treating nervous headache and preparation method thereof | |
| CN103083531B (en) | Drug for treating diabetes | |
| CN102274361A (en) | Anticancer medicinal composition and preparation method of decoction thereof | |
| CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN104162094A (en) | Traditional Chinese medicine composition for treating obese polycystic ovary syndrome, and medicinal preparation thereof | |
| CN102114074A (en) | Traditional Chinese medicine for treating diabetic diarrhea | |
| CN104206595A (en) | Blood lipid and blood glucose reducing Chinese wolfberry root-bark health care tea and preparation method thereof | |
| CN104856036B (en) | Health care medicated diet for treating iron-deficiency anemia and preparation method of health care medicated diet | |
| CN103330914A (en) | Traditional Chinese medicine composition for treating chronic gastritis | |
| CN103417911B (en) | Traditional Chinese medicine composition for supporting chemo-treatment | |
| CN104367926A (en) | Traditional Chinese medicine preparation for treating predawn diarrhea and preparation method thereof | |
| CN100336555C (en) | Danshen capsule for antitumour and its preparation technology | |
| CN101987188B (en) | Biological Chinese patent drug for preventing and treating hyperlipoidemia | |
| CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
| CN104857377A (en) | Traditional Chinese medicine extract for improving fatty liver, preparation method of traditional Chinese medicine extract and massage cream | |
| CN104162090B (en) | Pharmaceutical composition and preparation method thereof | |
| CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
| CN114712470B (en) | Medicine for treating deficiency of kidney of men and preparation method thereof | |
| CN1064536C (en) | Full-divergence promoting medicine for curing fourth-phase carcinoma of stomach and its processing method | |
| CN106334140A (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN104645247A (en) | Traditional Chinese medicine preparation for treating hepatolenticular degeneration and preparation method of traditional Chinese medicine preparation | |
| CN104606537A (en) | Qi-reinforcing and blood-nourishing medicated diet for improving chemotherapy-induced myocardial ischemic injury and preparation method | |
| CN114533835A (en) | Medicine with effects of aroma and dispelling wind and promoting diuresis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Sun Lihua Document name: Correction notice |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Lu Ping Document name: Notice of publication of application for patent for invention |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Lu Ping Document name: Deemed as a notice of withdrawal (Trial) |
|
| ASS | Succession or assignment of patent right |
Owner name: WANG YANGUANG Free format text: FORMER OWNER: LU PING Effective date: 20070202 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070202 Address after: 250013, No. 2, unit 18, building 202, three District, South District, Lixia District, Shandong, Ji'nan Applicant after: Wang Yanguang Address before: 100005 Beijing city Dongcheng District North Ao Hutong No. 53 Applicant before: Lu Ping |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG LUYIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG YANGUANG Effective date: 20150227 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250013 JINAN, SHANDONG PROVINCE TO: 276017 LINYI, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150227 Address after: 276017 Torch Road 145, hi tech Industrial Development Zone, Shandong, Linyi Patentee after: SHANDONG LUYIN PHARMACEUTICAL Address before: 250013, No. 2, unit 18, building 202, three District, South District, Lixia District, Shandong, Ji'nan Patentee before: Wang Yanguang |
|
| ASS | Succession or assignment of patent right |
Owner name: WANG QI Effective date: 20150325 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150325 Address after: 276017 Torch Road 145, hi tech Industrial Development Zone, Shandong, Linyi Patentee after: SHANDONG LUYIN PHARMACEUTICAL Patentee after: Wang Qi Address before: 276017 Torch Road 145, hi tech Industrial Development Zone, Shandong, Linyi Patentee before: SHANDONG LUYIN PHARMACEUTICAL |
|
| CX01 | Expiry of patent term |
Granted publication date: 20070912 |
|
| CX01 | Expiry of patent term |